Nautilus Biotechnology (NAUT) Current Leases (2020 - 2026)

Nautilus Biotechnology has disclosed Current Leases across 7 years of filings, most recently posting $3.9 million for Q1 2026.

• Current Leases for Q1 2026 came in at $3.9 million, down 9.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.9 million (down 9.19% YoY), and the FY2025 annual result was $3.8 million, down 6.47% from the prior year.
• Current Leases came in at $3.9 million for Q1 2026 at Nautilus Biotechnology, up from $3.8 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $4.2 million in Q1 2025 to a low of $1.5 million in Q1 2022.
• The 5-year median for Current Leases is $3.7 million (2024), against an average of $3.3 million.
• Across the five-year window, Current Leases soared 419.75% in 2022 and declined 9.19% in 2026, its largest moves.
• Nautilus Biotechnology's Current Leases stood at $2.0 million in 2022, then soared by 77.7% to $3.5 million in 2023, then rose by 15.8% to $4.1 million in 2024, then decreased by 6.47% to $3.8 million in 2025, then advanced by 0.52% to $3.9 million in 2026.
• The last three Current Leases figures came in at $3.9 million (Q1 2026), $3.8 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.